Pfizer Inc (PFE) News & EventsPFEPfizer Inc

Pfizer Shares Up 0.24% to $27.48

Moderately bullish activity in Pfizer (PFE), with shares up 6c, or 0.24%, near $27.48. Options volume roughly in line with average with 38k contracts traded and calls leading puts for a put/call ratio of 0.6, compared to a typical level near 0.48. Implied volatility (IV30) is higher by 1.0 points near 25.51,in the top quartile of the past year, suggesting an expected daily move of $0.44. Put-call skew steepened, indicating increased demand for downside protection.

Pfizer's LITFULO Trial Results Show Significant Efficacy for Vitiligo

Pfizer presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO as a once-daily oral treatment across a wide range of disease extent. In the two studies, TRANQUILLO 2 and TRANQUILLO, LITFULO 100 mg and 50 mg, respectively, significantly improved facial and total body repigmentation compared to placebo. These improvements were supported by patient-reported outcomes indicating reduced disease severity and meaningful change in facial and total body vitiligo, as well as greater disease stabilization compared to placebo. These results from the largest Phase 3 program to date evaluating an oral systemic therapy for nonsegmental vitiligo were presented today in a late-breaking oral presentation at the 35th European Academy of Dermatology and Venereology Annual Congress in Vienna, Austria. Pfizer intends to submit these data to regulatory authorities globally, including the U.S. Food and Drug Administration and European Medicines Agency for review. Key Results from TRANQUILLO Studies: 21.86% and 12.47% of patients taking LITFULO achieved F-VASI75 (greater than or equal to75% improvement in Facial Vitiligo Area Scoring Index) compared to 2.40% and 2.48% on placebo, respectively. 13.02% and 8.98% of patients taking LITFULO achieved T-VASI50 (greater than or equal to50% improvement in Total Vitiligo Area Scoring Index) compared to 2.40% and 1.98% on placebo, respectively. LITFULO achieved statistically significant and clinically meaningful improvements compared to placebo across multiple measures of facial and total body repigmentation. Across both trials, significant improvements from baseline in F-VASI and T-VASI were seen as early as Week 24 and increased through Week 36 and Week 52 compared to placebo. Additionally, more patients on LITFULO achieved clinically meaningful improvements at earlier timepoints, as measured by F-VASI75 and T-VASI50 at Week 24 and Week 36 compared to placebo. LITFULO also significantly reduced patient-reported facial and overall disease severity compared to placebo at Week 52.